Effects of single and concurrent intermittent administration of human PTH (1-34) and incadronate on cancellous and cortical bone of femoral neck in ovariectomized rats

被引:15
|
作者
Zhang, L [1 ]
Endo, N [1 ]
Yamamoto, N [1 ]
Tanizawa, T [1 ]
Takahashi, HE [1 ]
机构
[1] Niigata Univ, Sch Med, Dept Orthoped Surg, Niigata 9518510, Japan
关键词
femoral neck; bone histomorphometry; concurrent treatment; parathyroid hormone; incadronate;
D O I
10.1620/tjem.186.131
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The purpose of this study is to determine the efficacy of concurrent treatment with human parathyroid hormone, hPTH (1-34), and bisphosphonate (incadronate) in augmenting cortical and cancellous bone mass of femoral neck in ovariectomized (OVX) rats. Forty-eight 11-week-old female Sprague-Dawley rats were divided into eight groups (six animals in each group). The baseline control group was killed at the beginning of the experiment, at 11 weeks of age, hn ovariectomy mas performed in thirty rats and twelve rats were subjected to a sham surgery. OVX rats were untreated for the first four weeks of postsurgery to allow for the development of moderate osteopenia. These animals were then subjected to various treatments with either PTH, incadronate, or PTH+ incadronate for a period of 4 weeks. Right proximal femora (femoral necks) were used for bone histomorphometry. After OVX 8 weeks, there was a significant decrease in cancellous bone mass and cortical bone area of femoral neck in the OVX rats when compared to the sham control rats. In OVX rats treated with PTH alone or PTH + incadronate were completely restored lost cancellous and cortical bone mass of femoral neck by increase bone formation. The bone formation parameters (OS/BS, MS/BS) and bone turnover (BFR/BV) seen with PTR plus incadronate were similar to those seen with PTH treatment alone. This indicates that incadronate did not blunt the anabolic action of PTH when used concurrently. Our results suggest the followings: 1) the femoral neck of OVX rats is a suitable sample site for preclinical studies of the prevention of bone loss induced by estrogen depletion; 2) concurrent use of incadronate did not blunt the anabolic effect of PTH; 3) concurrent treatment showed the best results in restoring cancellous and cortical bone mass; and 4) it had additional benefits for bone strength independent of that achieved by the increase in bone mass.
引用
收藏
页码:131 / 141
页数:11
相关论文
共 40 条
  • [31] Effects of the different administration frequencies of teriparatide (PTH [1-34]) on new bone formation of expanded midpalatal sutures in rats: A histomorphometric and micro-computed tomography analysis
    Koca, Cansu Gul
    Sadry, Sanaz
    Asker, Hasan
    cicek, Muhammet Fatih
    Kosehasanogullari, Meryem
    Kaya, Gurkan
    ORTHODONTICS & CRANIOFACIAL RESEARCH, 2021, 24 (03) : 449 - 457
  • [32] Effects of human parathyroid hormone 1–34 on bone loss and lumbar intervertebral disc degeneration in ovariectomized rats
    Yang Luo
    Shu-yang Li
    Fa-ming Tian
    Hui-ping Song
    Ying-ze Zhang
    Liu Zhang
    International Orthopaedics, 2018, 42 : 1183 - 1190
  • [33] The effects of combined human parathyroid hormone (1-34) and simvastatin treatment on osseous integration of hydroxyapatite-coated titanium implants in the femur of ovariectomized rats
    Tao, Zhou-Shan
    Zhou, Wan-Shu
    Tu, Kai-Kai
    Huang, Zheng-Liang
    Zhou, Qiang
    Sun, Tao
    Lv, Yang-Xun
    Cui, Wei
    Yang, Lei
    INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED, 2015, 46 (11): : 2164 - 2169
  • [34] Intermittent administration of PTH(1-34) regulates the osteoblastic differentiation of human periodontal ligament cells via protein kinase C- and protein kinase A-dependent pathways in vitro
    Lossdoerfer, S.
    Kraus, D.
    Abuduwali, N.
    Jaeger, A.
    JOURNAL OF PERIODONTAL RESEARCH, 2011, 46 (03) : 318 - 326
  • [35] RETRACTED: Effect of Intermittent Administration of hPTH(1-34) on Cortical Bone Geometry in Rats Treated with High-Dose Glucocorticoids (Retracted article. See vol. 64, pg. 57, 2021)
    Iwamoto, Jun
    Seki, Azusa
    Sato, Yoshihiro
    CHINESE JOURNAL OF PHYSIOLOGY, 2014, 57 (05): : 231 - 237
  • [36] Effect and safety of intermittent weekly administration of human parathyroid hormone 1-34 in patients with primary osteoporosis evaluated by histomorphometry and microstructural analysis of iliac trabecular bone before and after 1 year of treatment
    Takami Miki
    Kiyoshi Nakatsuka
    Hiroshi Naka
    Hideki Masaki
    Yasuo Imanishi
    Masako Ito
    Masaaki Inaba
    Hirotoshi Morii
    Yoshiki Nishizawa
    Journal of Bone and Mineral Metabolism, 2004, 22 : 569 - 576
  • [37] Effect and safety of intermittent weekly administration of human parathyroid hormone 1-34 in patients with primary osteoporosis evaluated by histomorphometry and microstructural analysis of iliac trabecular bone before and after 1 year of treatment
    Miki, T
    Nakatsuka, K
    Naka, H
    Masaki, H
    Imanishi, Y
    Ito, M
    Inaba, M
    Morii, H
    Nishizawa, Y
    JOURNAL OF BONE AND MINERAL METABOLISM, 2004, 22 (06) : 569 - 576
  • [38] Comparison of the abilities of human parathyroid hormone (hPTH)-(1-34) and [Leu27]-cyclo(Glu22-Lys26)-hPTH-(l-31)NH2 to stimulate femoral trabecular bone growth in ovariectomized rats
    Whitfield, JF
    Morley, P
    Willick, G
    MacLean, S
    Ross, V
    Isaacs, RJ
    Barbier, JR
    CALCIFIED TISSUE INTERNATIONAL, 1998, 63 (05) : 423 - 428
  • [39] Bone Morphogenetic Protein-7 Modifies the Effects of Insulin-Like Growth Factors and Intermittent Parathyroid Hormone (1-34) on Human Periodontal Ligament Cell Physiology In Vitro
    Lossdoerfer, Stefan
    Abuduwali, Nuersailike
    Jaeger, Andreas
    JOURNAL OF PERIODONTOLOGY, 2011, 82 (06) : 900 - 908
  • [40] Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: A comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893
    Stewart, AF
    Cain, RL
    Burr, DB
    Jacob, D
    Turner, CH
    Hock, JM
    JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (08) : 1517 - 1525